Kamran Muhammad, MD
Interventional Cardiology · Tulsa, OKNPI 1164406906
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 74.8% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $340,304, 3.6 times the $94,062 reported in 2019. Among interventional cardiology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,420 payments — averaging $959.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$1M
- Medtronic$296K
- Abbott$33K
- Boston Scientific$5K
- Ancora Heart, Inc.$5K
- Abiomed$1K
- plus $2K from 19 others
Across 219 payments — averaging $19,614 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$3.8M
- Medtronic$236K
- Abbott$236K
- Boston Scientific$8K
- Abiomed$17
What the payments were for
- Consulting fees$738,66654%
- Speaking & faculty fees$400,14429%
- Travel & lodging$201,64915%
- Food & beverage$21,3712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 754 | $1,019,031 |
| Medtronic(2 entities) | 495 | $296,412 |
| Abbott | 89 | $32,780 |
| Boston Scientific | 9 | $5,205 |
| Ancora Heart, Inc. | 23 | $4,596 |
| Abiomed | 20 | $1,410 |
| Jenavalve Technology, Inc. | 2 | $1,350 |
| Biocardia, Inc. | 1 | $316 |
| Heartflow, Inc. | 1 | $121 |
| Angiodynamics, Inc. | 1 | $93 |
| Silk Road Medical, Inc. | 2 | $78 |
| Johnson & Johnson | 4 | $67 |
| Cardiva Medical, Inc. | 1 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Novartis | 2 | $44 |
| Cardiac Dimensions, Inc. | 2 | $41 |
| Pfizer | 2 | $37 |
| Chiesi USA, Inc. | 1 | $32 |
| Surmodics, Inc. | 2 | $27 |
| Philips North America LLC | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Merck | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $17 |
| B. Braun Interventional Systems Inc. | 1 | $14 |
| Inari Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$891,531
- COREVALVE EVOLUT R$163,840
- CoreValve Evolut$128,567
- PASCAL$83,868
- NAVITOR$19,584
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$15,813
- Mitra Clip system$10,299
- Vitalyst$4,909
- AccuCinch$4,236
- JenaValve Pericardial TAVR System$1,350
- Impella$780
- SAPIEN 3 Ultra RESILIA$604
- EVOQUE$234
- Tendyne Mitral Valve System$218
- Accent Pacemaker$144
- MitraClip$138
- GENERAL - STENTS$115
- TRICLIP$113
- 3F$103
How this compares
$1,361,831 in reported general payments places this provider in the 95th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 13 | $110,113 |
| EliquisApixaban | 115 | $90,715 |
| JardianceEmpagliflozin | 60 | $48,442 |
| EntrestoSacubitril/Valsartan | 49 | $41,566 |
| Repatha SureclickEvolocumab | 12 | $8,135 |
| XareltoRivaroxaban | 11 | $7,100 |
| ClopidogrelClopidogrel Bisulfate | 279 | $1,988 |
| Atorvastatin Calcium | 144 | $1,536 |
| Metoprolol Succinate | 112 | $1,019 |
| Ezetimibe | 16 | $843 |
| Eplerenone | 15 | $707 |
| Potassium Chloride | 59 | $521 |
| Rosuvastatin Calcium | 31 | $320 |
| Spironolactone | 36 | $311 |
| Torsemide | 31 | $304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $48 | $110,11313 claims |
| PfizerEliquis | $37 | $90,715115 claims |
| NovartisEntresto | $44 | $41,56649 claims |
| Johnson & JohnsonXarelto | $67 | $7,10011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Tulsa
- Stanley ZimmermanTulsa$93K
- Matthew ComstockTulsa$69K
- Wayne LeimbachTulsa$68K
- Tom HuTulsa$57K
- Eugene IchinoseTulsa$49K
- Poorya FazelTulsa$29K
- Tucker HarrisonTulsa$19K
- Andrew KurklinskyTulsa$15K
- Stewart KatzTulsa$13K
- Arash KarnamaTulsa$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.